Posted by Michael Wonder on 28 Jan 2021
ICER publishes evidence report on roxadustat for treating anaemia in chronic kidney disease
28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient to determine if roxadustat is safer or more effective than erythropoiesis-stimulating agents; possibility exists for greater mortality than erythropoiesis-stimulating agents.
The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and value of roxadustat (FibroGen) for treatment of anaemia in chronic kidney disease.
